Mycophenolate Mofetil not checked

Roche

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 2 trial completes
Trials
22 active
29 in total · 28 in the EU
Targets
 

What this is

How it works
Antimetabolite Immunosuppressant FDA class
How it’s given
“MMF willl be administered at a target dose of 2.0 - 2.5 g/day in divided doses through Week 80.”In the company’s words, NCT04221477 on ClinicalTrials.gov
Tested for
Lupus Nephritis (2 trials)
Main trialPhase 3
“This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in participants with International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 class III or IV lupus nephritis (LN) when added on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids.”In the company’s words, NCT04221477 on ClinicalTrials.gov
Other names
NIMP · MMF

Other drugs for Lupus Nephritis

All 45 drugs for Lupus Nephritis

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials29

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 15 Aug 2024 A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
Phase 2Recruiting 15 Jun 2028 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Phase 3Completed 28 May 2024 A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 3Completed 4 Sep 2025 A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
Phase 2Authorised not given Complex immunomodulatory therapy for patients with immune thrombocytopenia (T-MEM)
Phase 4Authorised not given Upfront autologous hematopoietic stem cell transplantation versus immunosuppressive medication in early diffuse cutaneous systemic sclerosis: an international multicentre, open-label, randomized controlled trial (UPSIDE)
Phase 4Authorised not given Evaluation of the benefits of Administering immunosuppressive drugs as Single daily doses over the first Year after liver transplantation
Phase 4Authorised not given ElucidatiNg Immunosuppressant pharmacokinetic variabilities by investigating Gut Microbiota modulations After kidney transplantation - ENIGMA
Phase 2Authorised not given NECESSITY – « New Clinical End-points in patients with primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients »
Phase 4Authorised not given Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects
Phase 2/3Authorised not given EvER-ILD 3 : Evaluation of Efficacy and safety of Rituximab and mycophenolate mofetil combination in patients with Interstitial Lung Disease related to systemic sclerosis: a multicentre double-blind placebo-controlled randomized trial.
Phase 2/3Ended not given A multicenter, randomized, double-blind, placebo-controlled TRial evaluating Immunosuppressive treatment in patients with chronic virus-Negative Inflammatory cardiomyopaThY (TRINITY trial)
Phase 3/4Authorised not given Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, randomized, open-label, clinical trial
Phase 1/2Authorised not given A Phase I/IIa open label single ascending dose study to investigate the safety and tolerability of regulatory T cells as an adjunctive therapy in deceased-donor kidney recipients - ProTreg
Phase 1/2Authorised not given Phase-I/II trial to assess the safety and efficacy of Venetoclax in addition to sequential conditioning with Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for allogeneic blood stem cell transplantation in patients with MDS, CMML or sAML
Phase 4Ended not given CALCIGRAN FORTE AND DOSING OF IMMUNOSUPPRESSIVE DRUGS IN KIDNEY TRANSPLANT RECIPIENTS
Phase 3Authorised not given OBILUP. Induction therapy for lupus nephritis with no added oral corticosteroids : An open label randomised multicentre controlled trial comparing oral corticosteroids plus mycophenolate mofetil (MMF) versus Obinutuzumab and MMF.
Phase 4Ended not given The OPTIMIzE study;OPen label multicenter randomized Trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
Phase 3Authorised not given STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years
Phase 4Ended not given (IPCOM) Influence of Proton pump inhibitor CO-medication on the absorption of innovator and generic formulations of Mycophenolate mofetil
Phase 4Authorised not given Safety and efficacy of steering of immunosuppression based on BKPyV-specific T cells in case of BK Polyomavirus (BKPyV) DNAe- mia after kidney transplantation
Phase 4Authorised not given SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA
Phase 4Authorised not given A randomized trial of tacrolimus monotherapy compared to standard triple immune suppressive medication in elderly recipients of a kidney transplant to reduce infection-related mortality and improve quality of life; the TACMONO-XL study.
Phase 4Authorised not given MULTICENTER, RANDOMIZED STUDY TO EVALUATE THE EFFICACY OF INDIVIDUALIZATION OF IMMUNOLOGICAL RISK BASED ON SELECTIVE BIOMARKERS (HLA EPLETH DISPARITY AND IFN-γ ELISPOT) TO OPTIMIZE IMMUNOSUPPRESSIVE TREATMENT IN LIVING DONOR KIDNEY TRANSPLANT PATIENTS (BIOIMMUN)
Phase 4Ended not given Immunosuppressive drug bioequivalence in kidney transplant recipients – Prograf and CellCept
Phase 4Authorised not given PRIMO : Precision immunosuppressive drug monitoring in liver transplantation: a randomized control trial
Phase 3Authorised not given Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe year AfTer lIver transplantatiON (ALTERNATION) – a randomized, prospective, multicenter, open-label, controlled phase III trial
Phase 4Authorised not given HORUS-Cytomegalovirus Open Proof-of-concept Exploratory trial
Phase 4Authorised not given Influence of Antimicrobial Drugs on Mycophenolic acid and Tacrolimus Pharmacokinetics and the Gut Microbiome in Kidney Transplant Recipients (AXIS)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Mycophenolate Mofetil

Following is part of Solo: you see every change to Mycophenolate Mofetil the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in